Page 32 - Journal of Structural Heart Disease Volume 2, Issue 5

233
our study group in subsequent randomized trials?
• Based on the safety of PFO devices [15], is it reasonable to address a cohort with headaches less recalcitrant than migraine?
• Can we de ne a PFO or RLS headache? Are there other substrates lacking chemical conversion by the pulmonary circulation in these patients?
In conclusion, Tayaka and colleagues have deepened our knowledge base. However, investigators must ex- pand our inquiry to the basic science linking right-to-left circulation and headaches. Migraines are one of the most debilitating diseases, and, if a safe and simple car-
Letter to the Editor
diac procedure is to be provided in hopes of improving our patient’s health and quality of life in their prime, it is imperative that we cement the construct between mi- graine, RLS, and this therapy.
Con ict of Interest
The authors have no con ict of interest relevant to this publication.
Comment on this Article or Ask a Question
References
1. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and bur- den of migraine in the United States: data from the American Migraine Study II. Head- ache. 2001;41:646-657. DOI: 10.1046/j.1526- 4610.2001.041007646.x
2. Stewart WF, Lipton RB, Simon D. Work-re- lated disability: results from the American migraine study. Cephalalgia. 1996;16:231- 238; discussion 215. DOI: 10.1046/j.1468- 2982.1996.1604231.x
3. Wilmshurst PT, Nightingale S, Walsh KP, Morrison WL. E ect on migraine of closure of cardiac right-to-left shunts to prevent recurrence of decompression illness or stroke or for haemodynamic reasons. Lan- cet. 2000;356:1648-1651. DOI: 10.1016/ S0140-6736(00)03160-3
4. Reisman M, Christo erson RD, Jesurum J, Olsen JV, Spencer MP, Krabill KA, et al. Migraine headache relief after transcath- eter closure of patent ovale. J Am Coll Cardiol. 2005;45:493-495. DOI: 10.1016/j. jacc.2004.10.055
5. Post MC, Thijs V, Herroelen L, Budts WI. Clo- sure of a patent foramen ovale is associated with a decrease in prevalence of migraine. Neurology. 2004;62:1439-1440. DOI: 10.1212/01.WNL.0000120756.25236.37
6. Schwerzmann M, Nedeltchev K, Lagger F, Mattle HP, Windecker S, Meier B, et al. Prevalence and size of directly detected patent foramen ovale in migraine with aura. Neurology. 2005;65:1415-1418. DOI: 10.1212/01.wnl.0000179800.73706.20
7. Lamy C, Giannesini C, Zuber M, Arquizan C, Meder JF, Trystam D, et al. Clinical im- aging ndings in cryptogenic stroke pa- tients with and without patent foramen ovale: the PFO-ASA Study. Atrial Septal Aneurysm. Stroke. 2002;33:706-711. DOI: 10.1161/hs0302.104543
8. Azarbal B, Tobis J, Suh W, Chan V, Dao C, Gaster R. Association of interatrial shunts and migraine headaches: impact of transcatheter closure. J Am Coll Car- diol. 2005;45:489-492. DOI: 10.1016/j. jacc.2004.09.075
9. Rodés-Cabau J, Molina C, Serrano-Munue- ra C, Casaldáliga J, Alvarez-Sabin J, Evan- gelista A, et al. Migraine with aura related to the percutaneous closure of an atrial septal defect. Catheter Cardiovasc Interv. 2003;60:540-542. DOI: 10.1002/ccd.10713
10. Wertman B, Azarbal B, Riedl M, Tobis J. Ad- verse events associated with nickel allergy in patients undergoing percutaneous atrial septal defect or patent foramen ovale clo- sure. J Am Coll Cardiol. 2006;47:1226. DOI: 10.1016/j.jacc.2005.12.017
11. Dowson A, Mullen MJ, Peat eld R, Muir K, Khan AA, Wells C, et al. Migraine Interven- tion With STARFlex Technology (MIST) Trial: a prospective, multicenter, double-blind, sham-controlled trial to evaluate the e ectiveness of patent foramen ovale closure with STARFlex septal repair implant to resolve refractory migraine headache. Circulation. 2008;117:1397-1404. DOI: 10.1161/CIRCULATIONAHA.107.727271
12. Takaya Y, Akagi T, Kijima Y, Nakagawa K, Kono S, Deguchi K, Sano S, Ito H. Reso- lution of Migraine After Transcatheter Closure of Atrial Communication. Struc- tural Heart Disease. 2016;2:102-107. DOI: 10.12945/j.jshd.2016.010.15
13. van der Kuy PH, Lohman JJ. A quanti ca- tion of the placebo response in migraine prophylaxis. Cephalalgia. 2002;22:265-270. DOI: 10.1046/j.1468-2982.2002.00363.x
14. Charles A for the PREMIUM Investigators. Late breaking trial: Prospective, Random- ized Investigation to Evaluate Incidence of Headache Reduction in Subjects with Migraine and PFO Using the Amplatzer PFO Occluder to Medical Management. June 26, 2015. Presentation for the 57th Annual American Headache Society. Washington DC.
15. Carroll JD, Saver JL, Thaler DE, Smalling RW, Berry S, MacDonald LA, et al. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. J Am Coll Cardiol. 2013;368:1092-100. DOI: 10.1056/ NEJMoa1301440
Reisman, M. et al.
Migraine and Interatrial Septal Defects
Cite this article as: Reisman M, Perpetua EM. Migraine Reduction After Transcatheter Closure of Interatrial Septal Defects: Another Brick in the Wall? Structural Heart Disease. 2016;2(5):231-233. DOI: http://dx.doi. org/10.12945/j.jshd.2016.012.15